{"id":72,"date":"2025-04-01T18:01:00","date_gmt":"2025-04-01T16:01:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=cde609f1661bfbe9a1ec27c99cd9225e"},"modified":"2025-04-01T18:01:00","modified_gmt":"2025-04-01T16:01:00","slug":"unlearn-and-trace-neuroscience-partner-to-optimize-als-clinical-trial","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=72","title":{"rendered":"Unlearn and Trace Neuroscience Partner to Optimize ALS Clinical Trial"},"content":{"rendered":"

\nCollaboration will support trial planning for Trace Neuroscience\u2019s upcoming Phase 1\/2 clinical trial in ALS<\/i>\n<\/p><\/a><\/a>

SAN FRANCISCO & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Unlearn\u00ae, a leader in AI-powered solutions for clinical trials, today announced a collaboration with Trace Neuroscience, a biotechnology company focused on developing genomic therapies for neurodegenerative diseases. The partnership will support Trace Neuroscience as the company plans its upcoming Phase 1\/2 clinical trial in amyotrophic lateral sclerosis (ALS), using Unlearn\u2019s Digital Twin Generator for ALS (ALS DTG) and the Unlearn Platform.\n<\/p>

\n\u201cTrace Neuroscience is advancing its development program targeting the UNC13A protein, a genetic target directly linked to ALS progression, and we\u2019re proud to support their mission by helping lay the foundation for more efficient trials and faster paths to potential treatments,\u201d said Steve Herne, CEO of Unlearn.\n<\/p>

\nThrough the partnership, Trace Neuroscience will leverage Unlearn\u2019s ALS DTG, a proprietary machine-learning model trained on more than 13,000 longitudinal clinical records from sources including APST, PRO-ACT, and NEALS. DTGs forecast how individual patients are likely to progress under standard of care or in the placebo group of a clinical trial, creating a \u201cdigital twin\u201d for each trial participant based on their baseline data.\n<\/p>

\nUnlearn\u2019s ALS DTG is a powerful tool to simulate disease progression, assess the relationship between disease status at baseline, clinical endpoints, and biomarkers over time, and enables partner companies to take actionable steps to optimize their clinical programs. Trace Neuroscience will utilize the ALS DTG to inform protocol decisions, such as specific inclusion and exclusion criteria and endpoint strategies, with the goal of increasing trial power and confidence in detecting both clinical and biomarker-based efficacy signals.\n<\/p>

\n\u201cThis collaboration brings together two powerful approaches\u2014AI and genomic medicine\u2014to rethink how ALS trials are designed,\u201d said Eric Green, M.D., Ph.D., co-founder and CEO of Trace Neuroscience. \u201cWorking with Unlearn to mine their extensive, well-curated database through the use of the ALS DTG will enable us to explore smarter designs and make confident and informed decisions as we plan our Phase 1\/2 trial. Ultimately, these insights can help us to move faster for people living with ALS who are waiting for new treatment options.\u201d\n<\/p>

\nThis partnership reflects both companies\u2019 commitment to bringing scientifically rigorous, innovative therapies to the ALS community with greater speed and confidence. Unlearn and Trace Neuroscience also plan to co-author scientific publications emerging from this work.\n<\/p>

\nFor more information, visit www.unlearn.ai<\/a> or follow us on LinkedIn and X\/Twitter.\n<\/p>

\nAbout Trace Neuroscience\n<\/p>

\nTrace Neuroscience is a biopharmaceutical company on a mission to expand the promise of genomic medicine for people living with neurodegenerative diseases. With an initial focus on ALS, the company is developing novel therapies to restore UNC13A protein function to re-establish healthy communication between nerves and muscle cells. Trace Neuroscience launched in 2024 with $101M in Series A funding led by Third Rock Ventures and is headquartered in South San Francisco, CA. Learn more at www.traceneuro.com<\/a>.\n<\/p>

\nAbout Unlearn\n<\/p>

\nUnlearn (www.unlearn.ai<\/a>) partners with pharma and biotech companies to design and optimize clinical trials using AI-powered digital twins. By forecasting patients\u2019 clinical outcomes, Unlearn helps sponsors refine trial design, shorten timelines, and increase the chance of detecting treatment effects in less time. With a science-first approach and deep regulatory engagement\u2014including EMA qualification and FDA endorsement\u2014Unlearn is transforming clinical development to be faster, smarter, and more reliable.\n<\/p> Contacts<\/b>

\nAlyssa Horowitz\nunlearn@pancomm.com<\/a>\n<\/p>","protected":false},"excerpt":{"rendered":"

Collaboration will support trial planning for Trace Neuroscience\u2019s upcoming Phase 1\/2 clinical trial in ALS
\nSAN FRANCISCO & SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Unlearn\u00ae, a leader in AI-powered solutions for clinical trials, today announced a…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-72","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/72","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=72"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/72\/revisions"}],"predecessor-version":[{"id":73,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/72\/revisions\/73"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=72"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=72"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=72"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}